NeuroSense Therapeutics (NASDAQ:NRSN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research note published on Monday,Benzinga reports. D. Boral Capital currently has a $14.00 price target on the stock.

NRSN has been the topic of a number of other reports. Wall Street Zen downgraded NeuroSense Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Zacks Research raised NeuroSense Therapeutics to a “hold” rating in a report on Wednesday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 8th. Finally, Noble Financial upgraded shares of NeuroSense Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.00.

NeuroSense Therapeutics Trading Up 3.8%

Shares of NRSN stock opened at $0.84 on Monday. The company has a 50 day moving average price of $1.06 and a 200-day moving average price of $1.39. NeuroSense Therapeutics has a 52 week low of $0.76 and a 52 week high of $2.60.

Institutional Trading of NeuroSense Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Two Sigma Investments LP purchased a new position in shares of NeuroSense Therapeutics in the third quarter valued at about $26,000. Jane Street Group LLC bought a new stake in NeuroSense Therapeutics during the 2nd quarter valued at approximately $54,000. Finally, Squarepoint Ops LLC lifted its holdings in NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares in the last quarter. 1.04% of the stock is currently owned by institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.